Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity.
Ravi D
RD
Patel
Michael P
MP
Blair
Michael J
MJ
Shapiro
Steven J
SJ
Lichtenstein
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D018450:Disease Progression; D005865:Gestational Age; D006801:Humans; D052577:Infant, Extremely Low Birth Weight; D007231:Infant, Newborn; D058449:Intravitreal Injections; D012008:Recurrence; D012163:Retinal Detachment / Q000000981:diagnostic imaging; D012178:Retinopathy of Prematurity / Q000188:drug therapy*; D017211:Treatment Failure; D014463:Ultrasonography; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab